2019—2023年兰州市城关区疑似预防接种异常反应监测结果分析

Suspected Vaccination in Chengguan District of Lanzhou from 2019 to 2023 Analysis of Abnormal Reaction Monitoring Results

目的:分析2019—2023年兰州市城关区疑似预防接种异常反应(Adverse event following immunization,AEFI)监测情况,为预防AEFI的发生提供依据。方法:分别从中国疾病预防控制信息系统AEFI监测相关模块和甘肃省疾病预防控制综合管理平台免疫规划模块,收集2019—2023年城关区报告的AEFI个案数据、疫苗接种剂次数,对AEFI的报告发生率、发生AEFI的疫苗种类等特征进行分析。结果:2019—2023年城关区共报告AEFI病例2 107例,累计报告发生率为76.55/10万。其中,一般反应占98.72%,异常反应占0.33%,偶合症占0.90%,心因性反应占0.05%,报告发生率分别为75.57/10万、0.25/10万、0.69/10万、0.03/10万,无接种事故和疫苗质量事故报告。结论:2019—2023年城关区AEFI主要以一般反应为主,异常反应中以过敏为主,严重异常反应极为罕见。此外,2023年的AEFI监测敏感性较2021年和2022年显著提高,这表明监测系统效能在不断提升。

OBJECTIVE To analyze the monitoring status of suspected adverse event following immunization(AEFI)in Cheng⁃guan District of Lanzhou from 2019 to 2023,in order to understand the characteristics,reported incidence rate,types of adverse reactions,and sensitivity of AEFI monitoring in Chengguan District.METHODS The AEFI monitoring related modules of the China Disease Prevention and Control Information System and the Immunization Planning module of the Gansu Provincial Comprehensive Management Platform for Disease Prevention and Control were used to collect data on AEFI reported cases from 2019 to 2023,as well as the number of vaccine doses administered.The incidence of adverse reaction reports,types of adverse reaction vaccines,and other characteristics were analyzed using Excel.From 2019 to 2023,a total of 2107 AEFI cases were reported in Chengguan District of Lanzhou,with a cumulative reported incidence rate of 76.55/105 doses;General reactions accounted for 98.72%,abnor⁃mal reactions accounted for 0.33%,coupling diseases accounted for 0.90%,and psychogenic reactions accounted for 0.05%.The reported incidence rates were 75.57/105,0.25/105,0.69/105,and 0.03/105,respectively.There were no vaccination accidents or vaccine quality accidents reported.CONCLUSION From 2019 to 2023,the adverse reactions of AEFI in Chengguan District were mainly general reactions,while allergic reactions were the main abnormal reactions,and severe abnormal reactions were extremely rare.In addition,the sensitivity of abnormal reaction monitoring in 2023 has significantly improved compared to 2021 and 2022,indicating that the effectiveness of the monitoring system is constantly improving.